VANCOUVER,
April 29, 2014 /CNW/ - iCo
Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF),
today announced that research collaborators will make a poster
presentation at the Association for Research in Vision and
Ophthalmology 2014 Annual Meeting. The Meeting is being held
from May 4th - 8th, 2014
in Orlando, Florida.
"The data being presented outlines patient
demographics and baseline characteristics of each arm of the phase
two iDEAL study, as well as the trial design and objectives," said
Peter Hnik, MD, Chief Medical
Officer of iCo Therapeutics. "The poster provides a great
context to the upcoming phase two study's primary data at month
eight and secondary data at month 12."
"More treatment options are needed for
individuals with diabetic macular edema" said Helen Nickerson, Ph. D., Senior Scientific
Program Manager for Complications Therapies at JDRF. "JDRF is
pleased to collaborate in the iDEAL study and grateful to the
investigators, physicians and patients involved. We eagerly
anticipate results from this important study."
The poster, titled "Demographics and Baseline
Characteristics of the iDEAL Study: A Randomized, Multi-center,
Phase II Study of the safety, Tolerability, and Bioactivity of
Repeated Intravitreal Injections of iCO-007 as Monotherapy or in
Combination with Ranibizumab or Laser Photocoagulation in the
Treatment of Diabetic Macular Edema with Involvement of the FoveAL
Center" is being presented by Dr. Quan Dong
Nguyen et al and will be presented from 11:00 am ET - 12:45 pm ET on Monday, May 5. The poster presents the
design, demographics, and baseline characteristics of the iDEAL
Study, as well as the inclusion/exclusion criteria and
characteristics by randomized treatment group.
About JDRF
JDRF is the leading global organization funding type 1 diabetes
(T1D) research. JDRF's goal is to progressively remove the
impact of T1D from people's lives until we achieve a world without
T1D. JDRF collaborates with a wide spectrum of partners and
is the only organization with the scientific resources, regulatory
influence, and a working plan to better treat, prevent, and
eventually cure T1D. As the largest charitable supporter of
T1D research, JDRF is currently sponsoring $568 million in scientific research in 17
countries. For more information, please visit www.jdrf.org.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates
or generics by employing reformulation and delivery technologies
for new or expanded use indications. The Company has exclusive
worldwide rights to two drug candidates - iCo-007 for Diabetic
Macular Edema (DME) and iCo-008 for other sight-threatening
diseases. iCo-007 is in Phase 2 clinical studies for DME. With
Phase 2 clinical history, iCo-008 is targeted for the treatment of
keratoconjunctivitis and wet age-related macular degeneration. In
addition, iCo holds worldwide rights to an oral drug delivery
platform. The first platform candidate is the Oral Amp B Delivery
system, utilizing a known anti-fungal drug to treat
life-threatening infectious diseases. iCo trades on the TSX Venture
Exchange under the symbol "ICO" and the OTCQX under the symbol
"ICOTF". For more information, visit the Company website at:
www.icotherapeutics.com.
No regulatory authority has approved or
disapproved the content of this press release. Neither the TSX
Venture Exchange nor its Regulatory Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward Looking Statements
Certain statements included in this press release may be
considered forward-looking statements" within the meaning of
applicable securities laws. Forward-looking statements can be
identified by words such as: "anticipate," "intend," "plan,"
"goal," "seek," "believe," "project," "estimate," "expect,"
"strategy," "future," "likely," "may," "should," "will," and
similar references to future periods and includes, but is not
limited to, statements about the intended use of proceeds of the
Offering. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should
not be read as guarantees of future performance or results. All
forward-looking statements are based on iCo's current beliefs as
well as assumptions made by and information currently available to
iCo and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which are based only on information currently available
to iCo and speak only as of the date of this press release. Due to
risks and uncertainties, including the risks and uncertainties
identified by iCo in its public securities filings and on its
website, actual events may differ materially from current
expectations. iCo disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by
law.
SOURCE iCo Therapeutics Inc.
